| Candesartan | heart failure, in patients with preserved-LVEF heart failure | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CHARM preserved, 2003 | candesartan target dose 32 mg once daily | placebo | patients with NYHA II-IV heart failure and LVEF higher than 40% |
| |
| Irbesartan | heart failure, in patients with preserved-LVEF heart failure | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | 0.97 [0.84 1.13] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | death or cardiovascular hospitalization | 0.97 [0.85 1.10] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Cardiovascular death | 1.03 [0.86 1.22] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | hospitalisation for heart failure | 0.96 [0.82 1.14] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Hospitalization for any reason | 1.02 [0.90 1.15] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 1.02 [0.88 1.18] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), |
| Trial | Studied treatment | Control | Patients |
|---|
| I-PRESERVE (McMurray), 2008 | ibersatan 300mg daily | placebo | patients with NYHA
II, III, or IV heart failure and an ejection fraction of at least 45% |
| |
| Telmisartan | patients at high risk for cardiovascular events, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.88 [0.76 1.02] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Cardiovascular death | 1.02 [0.85 1.24] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | stroke (fatal and non fatal) | 0.83 [0.64 1.07] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Coronary event | 0.79 [0.62 1.02] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Coronary death | no data | | cardiovascular death, MI, stroke | 0.88 [0.76 1.02] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Non fatal MI | no data | | Revascularization | 0.90 [0.77 1.05] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | All cause death | 1.05 [0.90 1.23] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Cough | 0.84 [0.42 1.67] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Hypotension | 1.82 [0.99 3.36] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | angiodema | 0.67 [0.11 4.02] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, | | Adverse events leading to treatment discontinuation | 0.91 [0.81 1.03] | p=1.00 | 0 | 5926 | 1 | TRANSCEND, |
| Trial | Studied treatment | Control | Patients |
|---|
| TRANSCEND, 2008 | telmisartan 80 mg/day | placebo | high-risk patients intolerant to
angiotensin-converting enzyme inhibitors |
| |
| Telmisartan | | vs ramipril | Hypotension by 54% adverse event Cough by 74% suggested angiodema by 60% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.99 [0.91 1.08] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Cardiovascular death | 1.00 [0.89 1.12] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | stroke (fatal and non fatal) | 0.91 [0.79 1.06] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Coronary event | 1.07 [0.93 1.23] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Coronary death | no data | | cardiovascular death, MI, stroke | no data | | Non fatal MI | no data | | Revascularization | 1.02 [0.94 1.11] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | All cause death | 0.98 [0.89 1.07] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Cough | 0.26 [0.21 0.33] | p=0.04 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Hypotension | 1.54 [1.25 1.90] | p=0.04 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | angiodema | 0.40 [0.19 0.84] | p=0.04 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), | | Adverse events leading to treatment discontinuation | 0.94 [0.87 1.01] | p=1.00 | 0 | 17118 | 1 | ONTARGET (telmisartan alone), |
| Trial | Studied treatment | Control | Patients |
|---|
| ONTARGET (telmisartan alone), 2008 | telmisartan 80mg daily | ramipril 10 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage |
| |
| Enalapril | patients at high risk for cardiovascular events, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.88 [0.67 1.14] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | Cardiovascular death | 2.43 [0.47 12.59] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | stroke (fatal and non fatal) | 0.65 [0.26 1.60] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | Coronary event | no data | | Coronary death | no data | | cardiovascular death, MI, stroke | no data | | Non fatal MI | 0.56 [0.27 1.19] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | Revascularization | 0.90 [0.66 1.21] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | All cause death | 1.30 [0.45 3.76] | p=1.00 | 0 | 1328 | 1 | CAMELOT (enalapril), | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events leading to treatment discontinuation | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CAMELOT (enalapril), 2004 | Enalapril 20mg daily | Placebo | patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg |
| |
| Perindopril | heart failure, in patients with preserved-LVEF heart failure | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | 0.90 [0.46 1.75] | p=1.00 | 0 | 850 | 1 | PEP CHF, | | hospitalisation for heart failure | 0.64 [0.41 1.01] | p=1.00 | 0 | 850 | 1 | PEP CHF, | | All cause death | 0.90 [0.46 1.75] | p=1.00 | 0 | 850 | 1 | PEP CHF, |
| Trial | Studied treatment | Control | Patients |
|---|
| PEP CHF, 2006 | perindopril, 4 mg/day | placebo | patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram
suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease |
| |
| Perindopril | patients at high risk for cardiovascular events, in all type of patients | vs placebo | Cough by 406% adverse event Hypotension by 253% adverse event Adverse events leading to treatment discontinuation by 10% adverse event cardiovascular events by 19% suggested Coronary event by 23% suggested Non fatal MI by 22% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.81 [0.71 0.92] | p=0.04 | 0 | 12218 | 1 | EUROPA, | | Cardiovascular death | 0.86 [0.72 1.04] | p=1.00 | 0 | 12218 | 1 | EUROPA, | | stroke (fatal and non fatal) | 0.96 [0.73 1.27] | p=1.00 | 0 | 12218 | 1 | EUROPA, | | Coronary event | 0.77 [0.66 0.89] | p=0.04 | 0 | 12218 | 1 | EUROPA, | | Coronary death | no data | | cardiovascular death, MI, stroke | no data | | Non fatal MI | 0.78 [0.67 0.91] | p=0.04 | 0 | 12218 | 1 | EUROPA, | | Revascularization | 0.96 [0.85 1.08] | p=1.00 | 0 | 12218 | 1 | EUROPA, | | All cause death | 0.89 [0.77 1.03] | p=1.00 | 0 | 12218 | 1 | EUROPA, | | Cough | 5.06 [3.46 7.41] | p=0.04 | 0 | 12218 | 1 | EUROPA, | | Hypotension | 3.53 [2.06 6.05] | p=0.04 | 0 | 12218 | 1 | EUROPA, | | angiodema | no data | | Adverse events leading to treatment discontinuation | 1.10 [1.01 1.20] | p=0.04 | 0 | 12218 | 1 | EUROPA, |
| Trial | Studied treatment | Control | Patients |
|---|
| EUROPA, 2003 | perindopril 8 mg once daily | placebo | low-risk patients with stable coronary heart disease and no apparent heart failure |
| |
| Quinapril | patients at high risk for cardiovascular events, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.88 [0.59 1.32] | p=1.00 | 0 | 1750 | 1 | QUIET, | | Cardiovascular death | 0.92 [0.43 1.97] | p=1.00 | 0 | 1750 | 1 | QUIET, | | stroke (fatal and non fatal) | no data | | Coronary event | 0.88 [0.59 1.32] | p=1.00 | 0 | 1750 | 1 | QUIET, | | Coronary death | 0.92 [0.42 2.02] | p=1.00 | 0 | 1750 | 1 | QUIET, | | cardiovascular death, MI, stroke | no data | | Non fatal MI | 0.89 [0.56 1.42] | p=1.00 | 0 | 1750 | 1 | QUIET, | | Revascularization | 1.11 [0.83 1.47] | p=1.00 | 0 | 1750 | 1 | QUIET, | | All cause death | 0.99 [0.58 1.71] | p=1.00 | 0 | 1750 | 1 | QUIET, | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events leading to treatment discontinuation | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| QUIET, 2001 | Quinapril 20mg one daily | Placebo | patients with angiographic evidence of coronary artery disease without systolic leftventricular dysfunction |
| |
| Ramipril | patients at high risk for cardiovascular events, in all type of patients | vs placebo | Cough by 301% adverse event angiodema by 143% adverse event cardiovascular events by 21% suggested Cardiovascular death by 25% suggested stroke (fatal and non fatal) by 31% suggested cardiovascular death, MI, stroke by 21% suggested Non fatal MI by 19% suggested Revascularization by 13% suggested All cause death by 15% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.79 [0.71 0.88] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Cardiovascular death | 0.75 [0.64 0.88] | p=0.04 | 0 | 9297 | 1 | HOPE, | | stroke (fatal and non fatal) | 0.69 [0.56 0.85] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Coronary event | no data | | Coronary death | no data | | cardiovascular death, MI, stroke | 0.79 [0.71 0.88] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Non fatal MI | 0.81 [0.71 0.92] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Revascularization | 0.87 [0.78 0.97] | p=0.04 | 0 | 9297 | 1 | HOPE, | | All cause death | 0.85 [0.75 0.96] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Cough | 4.01 [3.15 5.10] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Hypotension | 1.26 [0.92 1.73] | p=1.00 | 0 | 9297 | 1 | HOPE, | | angiodema | 2.43 [1.01 5.87] | p=0.04 | 0 | 9297 | 1 | HOPE, | | Adverse events leading to treatment discontinuation | 1.06 [0.97 1.16] | p=1.00 | 0 | 9297 | 1 | HOPE, |
| Trial | Studied treatment | Control | Patients |
|---|
| HOPE, 2000 | ramipril 10 mg once per day orally | placebo | high-risk patients (55 years of age or older) with evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure |
| |
| Ramipril | | vs ramipril | Hypotension by 175% adverse event Adverse events leading to treatment discontinuation by 20% adverse event | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.00 [0.92 1.09] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Cardiovascular death | 1.04 [0.92 1.17] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | stroke (fatal and non fatal) | 0.93 [0.80 1.07] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Coronary event | 1.07 [0.93 1.23] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Coronary death | no data | | cardiovascular death, MI, stroke | no data | | Non fatal MI | no data | | Revascularization | 1.04 [0.95 1.13] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | All cause death | 1.06 [0.97 1.16] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Cough | 1.10 [0.95 1.27] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Hypotension | 2.75 [2.27 3.32] | p=0.04 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | angiodema | 0.73 [0.40 1.33] | p=1.00 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), | | Adverse events leading to treatment discontinuation | 1.20 [1.12 1.28] | p=0.04 | 0 | 17077 | 1 | ONTARGET (association vs ramipril), |
| Trial | Studied treatment | Control | Patients |
|---|
| ONTARGET (association vs ramipril), 2008 | telmisartan 80mg + ramipril 10mg daily | ramipril 10 mg daily
| patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage
|
| |
| Ramipril | | vs telmisartan | Cough by 323% adverse event Hypotension by 78% adverse event Adverse events leading to treatment discontinuation by 28% adverse event | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.01 [0.93 1.10] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Cardiovascular death | 1.04 [0.93 1.17] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | stroke (fatal and non fatal) | 1.02 [0.88 1.18] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Coronary event | 1.00 [0.87 1.15] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Coronary death | no data | | cardiovascular death, MI, stroke | no data | | Non fatal MI | no data | | Revascularization | 1.01 [0.93 1.10] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | All cause death | 1.08 [0.99 1.19] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Cough | 4.23 [3.37 5.32] | p=0.04 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Hypotension | 1.78 [1.51 2.10] | p=0.04 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | angiodema | 1.81 [0.83 3.92] | p=1.00 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), | | Adverse events leading to treatment discontinuation | 1.28 [1.19 1.37] | p=0.04 | 0 | 17044 | 1 | ONTARGET (association vs telmisartan), |
| Trial | Studied treatment | Control | Patients |
|---|
| ONTARGET (association vs telmisartan), 2008 | telmisartan 80mg + ramipril 10mg daily
| telmisartan 80 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage
|
| |
| Trandolapril | patients at high risk for cardiovascular events, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.83 1.13] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Cardiovascular death | 0.95 [0.76 1.20] | p=1.00 | 0 | 8290 | 1 | PEACE, | | stroke (fatal and non fatal) | 0.77 [0.56 1.05] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Coronary event | 0.97 [0.88 1.08] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Coronary death | no data | | cardiovascular death, MI, stroke | 0.94 [0.81 1.08] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Non fatal MI | 1.00 [0.83 1.21] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Revascularization | 0.92 [0.77 1.09] | p=1.00 | 0 | 8290 | 1 | PEACE, | | All cause death | 0.89 [0.76 1.05] | p=1.00 | 0 | 8290 | 1 | PEACE, | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events leading to treatment discontinuation | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PEACE, 2004 | Trandolapril at a target dose of 4 mg per day | Placebo | patients with stable coronary artery disease and
normal or slightly reduced left ventricular function |
| |
